Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191201 | 0.89 | CYP2C19 (0.38) | CYP2C19MEN1KMT2ACETPTSHR | |
| SCHEMBL165219 | 0.88 | CYP2C19 (0.34) | CYP2C19CPB2MEN1CYP2C9KMT2A | |
| SCHEMBL7971082 | 0.83 | CYP2C19 (0.33) | CYP2C19CETPKDM4EALDH1A1TSHR | |
| SCHEMBL5728858 | 0.79 | HDAC1 (0.33) | CPB2MEN1KMT2A | |
| SCHEMBL6056602 | 0.78 | CPB2 (0.34) | CYP2C19CPB2MEN1CYP2C9KMT2A | |
| SCHEMBL9526683 | 0.77 | ATM (0.41) | — | |
| SCHEMBL19767 | 0.76 | CPB2 (0.35) | CYP2C19CPB2MEN1CYP2C9KMT2A | |
| Hydrochloric Acid SCHEMBL9527859 | 0.75 | ATM (0.40) | — | |
| SCHEMBL15031561 | 0.75 | — | — | |
| SCHEMBL17049040 | 0.73 | CPB2 (0.39) | CPB2MEN1KMT2ACETPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-3138842-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| EP-2538784-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | disclosed |
| US-8895596-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2013043826-A1 | TRICYCLIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | ABBVIE INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2538784-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309736-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DONME CORP | 2012-12-06 | — | — | US | disclosed |
| WO-2011106273-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309736-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | CYP2C19 2611/4885CPB2 1798/4885MEN1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.